Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11396318 | 0.86 | AKR1C3 (0.51) | AKR1C3AKR1C2KMT2ARAB9AMEN1 | |
| SCHEMBL2422613 | 0.83 | ESR1 (0.57) | AKR1C3AKR1C2KMT2ACA1CA2 | |
| SCHEMBL8984177 | 0.83 | KMT2A (0.55) | AKR1C3AKR1C2KMT2AACHEALOX5 | |
| SCHEMBL9818100 | 0.83 | AKR1C3 (0.75) | AKR1C3AKR1C2KMT2ARAB9AMEN1 | |
| SCHEMBL5516974 | 0.83 | ESR1 (0.57) | AKR1C3AKR1C2KMT2ACA1CA2 | |
| SCHEMBL17084124 | 0.83 | KMT2A (0.55) | AKR1C3AKR1C2KMT2AACHEALOX5 | |
| SCHEMBL317875 | 0.83 | AKR1C3 (0.75) | AKR1C3AKR1C2KMT2ARAB9AMEN1 | |
| SCHEMBL5510967 | 0.83 | ESR1 (0.57) | AKR1C3AKR1C2KMT2ACA1CA2 | |
| SCHEMBL22838087 | 0.83 | KMT2A (0.55) | AKR1C3AKR1C2KMT2ARAB9AMEN1 | |
| SCHEMBL10707144 | 0.83 | KMT2A (0.47) | AKR1C3AKR1C2KMT2AMEN1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383893-A1 | Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof | HAIHE BIOPHARMA CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| EP-4400493-A1 | HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| CN-117980293-A | Hydroxamic acid compound with ENPP1 inhibitory activity and application thereof | 上海海和药物研究开发股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| EP-1838654-A1 | PROCESS FOR THE MANUFACTURE OF SUBSTITUTED PROPIONIC ACIDS | Phoenix Chemicals Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006075177-A1 | PROCESS FOR THE MANUFACTURE OF SUBSTITUTED PROPIONIC ACIDS | PHOENIX CHEMICALS LTD. (GB) | 2006-07-20 | — | — | WO | disclosed |
| EP-0151702-A2 | Alpha-hydroxyketone acetals | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1985-08-21 | — | — | EP | disclosed |
| EP-0048136-A2 | Process for preparing alpha-aromatic group substituted alkanoic acids or esters thereof | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1982-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383893-A1 | Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof | ENPP1, ENPP2, ENPP3 | AKR1C3 3859/4885AKR1C2 3060/4885KMT2A 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.